Lisocabtagene Maraleucel

The FDA published a safety advisory on the risk of T-cell malignancies among individuals receiving autologous chimeric antigen receptor T-cell therapy for the treatment of certain blood cancers.

The FDA announced several regulatory actions.

Novel targeted therapies have become standard treatment for chronic lymphocytic leukemia due to their ability to delay progression of this slow-growing malignancy.

An infusion of lisocabtagene maraleucel induced deep and durable responses among most adults with relapsed or refractory follicular lymphoma, according to results of the phase 2 TRANSCEND FL trial.

This year’s ASCO Annual Meeting included essential research updates across the field.

In this edition, FDA approves Vanflyta for newly diagnosed AML; liso-cel could have ‘best shot’ at remission for double refractory CLL; mortality factors among cancer survivors and more.

In this video, Jakub Svoboda, MD, discusses updated data on the results of lisocabtagene maraleucel chimeric antigen receptor T-cell therapy on chronic lymphocytic leukemia, presented at ASCO Annual Meeting.

In this edition, prior authorization linked delay in prescription fills; disparities in access to specialized cancer centers; ‘new potential treatment option’ for advanced chronic lymphocytic leukemia and more.

CHICAGO — Lisocabtagene maraleucel significantly improved complete remission rates among adults with relapsed or refractory chronic lymphocytic leukemia, results from the pivotal phase 2 TRANSCEND CLL 004 trial showed.

Two clinical trials evaluating lisocabtagene maraleucel met their primary endpoints by demonstrating meaningful overall response rates among adults with follicular or mantle cell lymphomas, according to the agent’s manufacturer.